Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

NAO.VNS: A New Personalized Neural Stimulation Therapy For Drug-resistant Epilepsy

Objective

19.5M world population suffer from Drug-Resistant Epilepsy (DRE) with symptoms poorly controlled. 8M are not eligible for brain surgery. Vagus nerve stimulation is nowadays the best treatment option. But unfortunately, current solutions do not reply to the clinical need. They cannot adapt to each patient making the patient's therapeutic journey complicated and expensive.

We created NAO.VNS the next-generation implantable vagus nerve neurostimulator. We replaced metal wires by optical fibres to convert optical energy to electrical impulses rendering the device compliant with MRI & brain scans essential for disease diagnosis or treatment. Through NAO.VNS patients & physicians receive remote feedback on the direct effect & efficacy of the neural stimulation, to precisely & uniquely adapt therapy.

Through EIC funding, we will complete a clinical pilot trial & a pivotal study in the EU/US to initiate market approvals. We expect to generate €89M by 2028 selling in the EU/US.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2022-ACCELERATOR-01

See all projects funded under this call

Coordinator

SYNERGIA MEDICAL
Net EU contribution
€ 2 499 000,00
Address
RUE EMILE FRANCQUI 6
1435 Mont-Saint-Guibert
Belgium
SME
Yes
Region
Région wallonne Prov. Brabant Wallon Arr. Nivelles
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 4 471 250,00